Skip to content
Screener

Arrowhead Research ARWR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$20.26M+1,474%
ALN
Alnylam PharmaceuticalsALNY
$33.56M-58.7%
Assembly Biosciences logo
Assembly BiosciencesASMB
$0-100%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$11.53M+335%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.5M-45.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.03M+182%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The source filing: Arrowhead Research’s 10-Q, filed February 5, 2026.

Filed
Feb 5, 2026, 4:06 PM EST
Fiscal quarter
Q1 FY2026
Calendar quarter
Q4 2025
Accession
0000879407-26-000034
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024
Proceeds from the exercises of stock options5,098634
Proceeds from the issuance of pre-funded warrants25,000
Payments of debt issuance costs(5,000)
Proceeds from the issuance of common stock, net of issuance costs paid46,832
Repayments of credit facility(66,680)
Net cash (used in) provided by financing activities(14,750)20,634
Net decrease in cash, cash equivalents and restricted cash(25,011)(48,728)
Effect of exchange rate on cash, cash equivalents and restricted cash106(68)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's stock issuance proceeds?
Arrowhead Research (ARWR) reported stock issuance proceeds of $46.83M in Q4 2025.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Arrowhead Research's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude